AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19389335 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 104
Study 19389335 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 104
Study 17564637 — intervention group
Group type: EXPERIMENTAL
Intervention: efalizumab 0.5 mg/kg weekly subcutaneously for 12 weeks
Number of subjects: 38
Study 17564637 — intervention group
Group type: EXPERIMENTAL
Intervention: efalizumab 2 mg/kg weekly subcutaneously for 12 weeks
Number of subjects: 38
Study 17564637 — intervention group
Group type: EXPERIMENTAL
Intervention: efalizumab (both doses)
Number of subjects: 38
Study 17564637 — intervention group
Group type: EXPERIMENTAL
Intervention: efalizumab (higher dose)
Number of subjects: 38
Study 14643816 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (DZX) group, 1.5 mg/kg diazoxide infused intravenously within 5 min followed by a 5‐min washout before CPB.
Number of subjects: 40
Study 14643816 — intervention group
Group type: COMPARATOR
Intervention: Control group, time‐matched period of placebo infusion.
Number of subjects: 40
Study 10480822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to treat analysis mentioned in reports
Number of subjects: 248
Study 10480822 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of patients who did not start the allocated intervention
Number of subjects: 248
Study 10480822 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of all randomised subjects as allocated
Number of subjects: 248
Study 10480822 — intervention group
Group type: EXPERIMENTAL
Intervention: No deviations from random allocation
Number of subjects: 248
Study 10480822 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis according to random allocation
Number of subjects: 248
Study 10480822 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing data on primary outcome variable
Number of subjects: 248
Study 10480822 — intervention group
Group type: EXPERIMENTAL
Intervention: Handling of missing responses
Number of subjects: 248
Study 10480822 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 10% of responses missing for primary outcome
Number of subjects: 248
Study 8910173 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct obturator nerve block with 15 ml of lidocaine (Group A, n = 20)
Number of subjects: 45
Study 8910173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral direct obturator nerve block with 30 ml of lidocaine (Group B, n = 12)
Number of subjects: 45
Study 8910173 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐in‐1 indirect obturator nerve block with 40 ml of lidocaine (Group C, n = 17)
Number of subjects: 45
Study 8910173 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Groups B and C to Group A
Number of subjects: 45
Study 8910173 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 45
Study 1676321 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow and peripheral blood stem cells (PBSC)
Number of subjects: 20
Study 7104161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral meptazinol (50 mg)
Number of subjects: 0
Study 7104161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral meptazinol (100 mg)
Number of subjects: 0
Study 7104161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral meptazinol (150 mg)
Number of subjects: 0
Study 7104161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral meptazinol (200 mg)
Number of subjects: 0
Study 7104161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29767467 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxy therapy
Number of subjects: 45
Study 29767467 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical peel
Number of subjects: 45
Study 29767467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C mesotherapy
Number of subjects: 45
Study 28445110 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (HYP; FiO2 0.12, SpO2 82±2%)
Number of subjects: 16
Study 28445110 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NOR; FiO2 0.21, SpO2 98±0%)
Number of subjects: 16
Study 25885012 — intervention group
Group type: COMPARATOR
Intervention: Psychostimulant plus parent training plus placebo (basic treatment)
Number of subjects: 150
Study 25885012 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulant plus parent training plus risperidone (augmented treatment)
Number of subjects: 150
Study 25885012 — intervention group
Group type: EXPERIMENTAL
Intervention: Responder status
Number of subjects: 150
Study 24035403 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2140023 (20mg twice daily)
Number of subjects: 167
Study 24035403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 167
Study 24035403 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2140023
Number of subjects: 167
Study 21926861 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (80 kV with 100 mL of contrast material)
Number of subjects: 84
Study 21926861 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (standard 120 kV with 150 mL of contrast material)
Number of subjects: 84
Study 19194995 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 40-100 mg
Number of subjects: 442
Study 19194995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 16505229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal ingestion
Number of subjects: 18
Study 16505229 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline infusion
Number of subjects: 18
Study 16304280 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic histamine challenge
Number of subjects: 47
Study 16304280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution challenge
Number of subjects: 47
Study 16304280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic histamine challenge
Number of subjects: 47
Study 10598692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2.0% dorzolamide and 0.5% timolol) administered twice daily plus placebo once daily
Number of subjects: 335
Study 10598692 — intervention group
Group type: COMPARATOR
Intervention: 2.0% Dorzolamide administered three times daily plus placebo once daily
Number of subjects: 335
Study 10598692 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Timolol administered twice daily plus placebo once daily
Number of subjects: 335
Study 8736372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermasorb
Number of subjects: 21
Study 8736372 — intervention group
Group type: COMPARATOR
Intervention: Jelonet
Number of subjects: 21
Study 1662636 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg single dose on day 1, followed by 250 mg once-daily on days 2-5)
Number of subjects: 119
Study 1662636 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (500 mg t.i.d. for 10 days)
Number of subjects: 119
Study 6754063 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate with Corynebacterium parvum
Number of subjects: 0
Study 6754063 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 0
Study 31861988 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of treated nets
Number of subjects: 175
Study 31861988 — intervention group
Group type: EXPERIMENTAL
Intervention: Working after dark
Number of subjects: 175
Study 31861988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing in a stream after dark
Number of subjects: 175
Study 31861988 — intervention group
Group type: EXPERIMENTAL
Intervention: Collecting water after dark
Number of subjects: 175
Study 29433850 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight <60 kg)
Number of subjects: 954
Study 29433850 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice-daily in 28-day cycles)
Number of subjects: 954
Study 25968450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic Skin Response (SSR) assessment in CLBP and FBSS patients
Number of subjects: 40
Study 25968450 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for pain intensity
Number of subjects: 40
Study 25968450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index (ODI) for perceived functional disability
Number of subjects: 40
Study 25968450 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic nerve conduction studies
Number of subjects: 40
Study 25968450 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 40
Study 24875610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1030
Study 24875610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1030
Study 22989921 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration of untreated negative symptoms (DUNS)
Number of subjects: 77
Study 22989921 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration of untreated positive symptoms (DUPS)
Number of subjects: 77
Study 22989921 — intervention group
Group type: COMPARATOR
Intervention: Long duration of untreated symptoms
Number of subjects: 77
Study 20430379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate 3 mg
Number of subjects: 0
Study 20430379 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (control)
Number of subjects: 0
Study 17919718 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cytological and HPV DNA testing
Number of subjects: 17155
Study 17919718 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytological testing only
Number of subjects: 17155
Study 16264400 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocinase plasma activity measured in pregnant women a few days before delivery.
Number of subjects: 160
Study 16264400 — intervention group
Group type: EXPERIMENTAL
Intervention: RCAS1 expression assessment by Western blot analysis.
Number of subjects: 160
Study 16264400 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of RCAS1 in placenta directly after delivery.
Number of subjects: 160
Study 16264400 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of immune tolerance at the moment of delivery.
Number of subjects: 160
Study 11899964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr supplements as brewer's yeast
Number of subjects: 78
Study 11899964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr supplements as CrCl3
Number of subjects: 78
Study 11899964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 11899964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr supplements (both types)
Number of subjects: 78
Study 11899964 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects responding to Cr supplement
Number of subjects: 78
Study 10078403 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose mivacurium (0.08 mg.kg‐1)
Number of subjects: 16
Study 10078403 — intervention group
Group type: COMPARATOR
Intervention: Low dose succinylcholine (0.5 mg.kg‐1)
Number of subjects: 16
Study 7723664 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight branched-chain amino acid (BCAA) infusion
Number of subjects: 8
Study 7723664 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study 2143459 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 44
Study 2143459 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 44
Study 31040207 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC + DTM
Number of subjects: 15
Study 31040207 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC + DTM (in responders)
Number of subjects: 15
Study 31040207 — intervention group
Group type: COMPARATOR
Intervention: HFNC alone
Number of subjects: 15
Study 28475619 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint condition (actors sharing a goal)
Number of subjects: 0
Study 28475619 — intervention group
Group type: COMPARATOR
Intervention: Parallel condition (actors acting alone)
Number of subjects: 0
Study 26329358 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 121
Study 26329358 — intervention group
Group type: COMPARATOR
Intervention: Rapid shallow breathing index (RSBI)
Number of subjects: 121
Study 26329358 — intervention group
Group type: COMPARATOR
Intervention: Maximum inspiratory pressure
Number of subjects: 121
Study 26329358 — intervention group
Group type: COMPARATOR
Intervention: RSBI at 1 min (RSBI1)
Number of subjects: 121
Study 26329358 — intervention group
Group type: COMPARATOR
Intervention: RSBI at 30 min (RSBI30)
Number of subjects: 121
Study 26329358 — intervention group
Group type: COMPARATOR
Intervention: Absolute percentage change in RSBI from 1 to 30 min (ΔRSBI30)
Number of subjects: 121
Study 23782681 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy (thrombus aspiration)
Number of subjects: 460
Study 23782681 — intervention group
Group type: COMPARATOR
Intervention: Conventional percutaneous coronary intervention (PCI) alone
Number of subjects: 460
Study 23782681 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 460
Study 23782681 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy and PCI
Number of subjects: 460
Study 21724263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal 1.25 mg/0.05 ml bevacizumab injection 1 to 14 days before PPV (Group 1)
Number of subjects: 91
Study 21724263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal 1.25 mg/0.05 ml bevacizumab injection at the end of PPV (Group 2)
Number of subjects: 91
Study 21724263 — intervention group
Group type: COMPARATOR
Intervention: No IVB injection (Group 3)
Number of subjects: 91
Study 19367173 — intervention group
Group type: EXPERIMENTAL
Intervention: EXPLORE intervention
Number of subjects: 4295
Study 18173006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactofem (1 capsule and 2 ml of gel every third day for one month)
Number of subjects: 55
Study 18173006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactofem (for asymptomatic BV)
Number of subjects: 55
Study 18173006 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (1 g daily for 7 days)
Number of subjects: 55
Study 14716182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal estriol (1 mg once daily for 2 weeks, then 2 ovules once weekly for 6 months)
Number of subjects: 88
Study 14716182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal estriol
Number of subjects: 88
Study 14716182 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo vaginal suppositories
Number of subjects: 88
Study 11549632 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg twice daily)
Number of subjects: 41
Study 11549632 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (500 mg twice daily)
Number of subjects: 41
Study 11549632 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 41
Study 11549632 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study 9506322 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week intensive exercise program (two 1-hour walking sessions per day and four 40-minute bicycle ergometer training sessions at 70% to 80% peak exercise capacity per week)
Number of subjects: 25
Study 9506322 — intervention group
Group type: COMPARATOR
Intervention: Sedentary life at home for 8 weeks
Number of subjects: 25
Study 7509244 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetorphan (300 mg)
Number of subjects: 20
Study 7509244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (5 mg)
Number of subjects: 20
Study 7509244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3044506 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms (one puff) given twice daily during 6-week treatment period
Number of subjects: 39
Study 3044506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one puff) given twice daily during 6-week control period
Number of subjects: 39
Study 30277997 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous titanium coating (PTC)
Number of subjects: 380
Study 30277997 — intervention group
Group type: COMPARATOR
Intervention: Plasma-sprayed titanium (PS)
Number of subjects: 380
Study 28693456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 1000
Study 28693456 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1000
Study 26267453 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Appropriate Hypertension Education (CAHE)
Number of subjects: 139
Study 26267453 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 139
Study 23152035 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 76
Study 21958782 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 20
Study 21958782 — intervention group
Group type: COMPARATOR
Intervention: Retrograde cardioplegia
Number of subjects: 20
Study 18328363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount-high-intensity aerobic exercise training
Number of subjects: 189
Study 16783607 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T polymorphism
Number of subjects: 1840
Study 16783607 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR A1298C polymorphism
Number of subjects: 1840
Study 16783607 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 1840
Study 12545290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg twice a day
Number of subjects: 32
Study 12545290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11013502 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration program (39 hours per week for 3 weeks)
Number of subjects: 99
Study 11013502 — intervention group
Group type: COMPARATOR
Intervention: Outpatient intensive physical training (1.5 hours three times per week for 8 weeks)
Number of subjects: 99
Study 8872871 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 0.5 mg scopolamine (SCO)
Number of subjects: 35
Study 8872871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 35
Study 1613528 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ultrasound
Number of subjects: 60
Study 1613528 — intervention group
Group type: COMPARATOR
Intervention: Venography
Number of subjects: 60
Study 6427609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg) four times daily
Number of subjects: 10
Study 6427609 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 10
Study 31454347 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of a preventive nutrition package including age-appropriate behavior change communication (BCC) and small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 2318
Study 29548623 — intervention group
Group type: EXPERIMENTAL
Intervention: RUSF-v (fortified with arginine and citrulline, daily chloroquine 3 mg/kg)
Number of subjects: 119
Study 29548623 — intervention group
Group type: EXPERIMENTAL
Intervention: RUSF-b (basic formulation, weekly chloroquine 150 mg or 225 mg)
Number of subjects: 119
Study 29548623 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RUSF interventions pooled
Number of subjects: 119
Study 29548623 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline and washout periods)
Number of subjects: 119
Study 26283011 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective vaporization using the 180‐W GreenLight GL‐XPS
Number of subjects: 281
Study 26283011 — intervention group
Group type: COMPARATOR
Intervention: Conventional (monopolar or bipolar) TURP
Number of subjects: 281
Study 26283011 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GL‐XPS and TURP
Number of subjects: 281
Study 26283011 — intervention group
Group type: EXPERIMENTAL
Intervention: Overactive Bladder Questionnaire Short Form
Number of subjects: 281
Study 24825872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonication method for diagnosis of catheter-related infections
Number of subjects: 975
Study 24825872 — intervention group
Group type: COMPARATOR
Intervention: Semiquantitative roll‐plate culture technique (SQC)
Number of subjects: 975
Study 22762844 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone 20 mg
Number of subjects: 30
Study 22762844 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone 30 mg (single dose)
Number of subjects: 30
Study 22762844 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone 60 mg
Number of subjects: 30
Study 22762844 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone 30 mg (repeated dosing)
Number of subjects: 30
Study 22762844 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 20164395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency electrical stimulation (HFS)
Number of subjects: 22
Study 20164395 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation
Number of subjects: 22
Study 18058736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 10
Study 18058736 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (OCTR-LAR)
Number of subjects: 10
Study 15044407 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingotomy without suturing (group I; n = 43)
Number of subjects: 97
Study 15044407 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingotomy with suturing (group II; n = 32)
Number of subjects: 97
Study 11120927 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal viral RNA levels >43,000 copies/mL
Number of subjects: 279
Study 11120927 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal cervical HIV-1 DNA
Number of subjects: 279
Study 11120927 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal HIV-1 DNA
Number of subjects: 279
Study 11120927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical or vaginal ulcers
Number of subjects: 279
Study 11120927 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 279
Study 11120927 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastitis
Number of subjects: 279
Study 11120927 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast abscess
Number of subjects: 279